Liver Transplantation News and Research RSS Feed - Liver Transplantation News and Research

LDLT effective for treating patients suffering from acute liver failure

LDLT effective for treating patients suffering from acute liver failure

When patients develop acute liver failure, severe complications arise rapidly after the first signs of liver disease, and patients' health can deteriorate rapidly. New research published in the American Journal of Transplantation indicates that emergency evaluations of living liver donors can be conducted safely to allow acute liver failure patients to undergo transplantation before their condition worsens. [More]
SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France. [More]
OTC medications, dietary and herbal supplements cause drug-induced acute liver failure

OTC medications, dietary and herbal supplements cause drug-induced acute liver failure

Drug-induced acute liver failure is uncommon, and over-the-counter medications and dietary and herbal supplements -- not prescription drugs -- are its most common causes, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
Possible cause of liver disease identified in adolescents with cystic fibrosis

Possible cause of liver disease identified in adolescents with cystic fibrosis

A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis. [More]
U of T's Marialena Mouzaki named Best International Abstract Awardee by A.S.P.E.N.

U of T's Marialena Mouzaki named Best International Abstract Awardee by A.S.P.E.N.

Marialena Mouzaki, MD, MSc, an assistant professor at University of Toronto and a staff gastroenterologist at Toronto's Hospital for Sick Children, has been named the Best International Abstract Awardee by the American Society for Parenteral and Enteral. The award is for her research on pediatric end-stage liver disease that she will present at A.S.P.E.N.'s Clinical Nutrition Week scientific conference in Long Beach, California, February 14 to 17. [More]
Three Keck Medicine scientists of USC receive $4.3 million from CIRM for stem cell research

Three Keck Medicine scientists of USC receive $4.3 million from CIRM for stem cell research

Three scientists from Keck Medicine of the University of Southern California have won grants exceeding $4.3 million from the California Institute for Regenerative Medicine for research that includes creating a temporary liver for transplant patients, finding novel ways to treat immune disorders and blood diseases and developing a new animal model for exploring diseases like heart failure, diabetes and neurodegenerative diseases. [More]
Marie Csete appointed president and chief scientist of HMRI

Marie Csete appointed president and chief scientist of HMRI

Huntington Medical Research Institutes, a leading biomedical research organization, has announced the appointment of Marie Csete, MD, PhD, its chief scientific officer, to her new role as president and chief scientist of HMRI. [More]
Dr. Hans Clevers receives ISSCR's McEwen Award for Innovation

Dr. Hans Clevers receives ISSCR's McEwen Award for Innovation

The International Society for Stem Cell Research has awarded Dr. Hans Clevers, senior author on two important papers published recently in the scientific journal Cell, the society's McEwen Award for Innovation. [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
Researchers develop novel method to predict risk of liver cancer recurrence after transplantation

Researchers develop novel method to predict risk of liver cancer recurrence after transplantation

UCLA transplantation researchers have developed a novel method that more accurately calculates the risk of disease recurrence in liver cancer patients who have undergone a liver transplant, providing a new tool to help physicians make treatment and surveillance decisions. [More]
Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences. [More]
Medical researchers at Saint Louis University bring hope to those in pain and sickness

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness. [More]
Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that a recent study provides new evidence for anti-cirrhotic effects of GFT505 in the context of NASH. [More]
Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

The American Gastroenterological Association Research Foundation is pleased to announce that Ashish Nimgaonkar, MBBS, MTech, MS, from John Hopkins University, has received the inaugural AGA-Boston Scientific Career Development Technology & Innovation Award. This award is graciously supported by a grant from Boston Scientific, a leading innovator of medical solutions. [More]
New treatment regimen for hepatitis C in transplant patients produces promising results

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine. [More]
Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol. [More]
Cedars-Sinai scientists test ELAD bioartificial liver support system for patients with acute liver failure

Cedars-Sinai scientists test ELAD bioartificial liver support system for patients with acute liver failure

Cedars-Sinai physicians and scientists are testing a novel, human cell based, bioartificial liver support system for patients with acute liver failure, often a fatal diagnosis. [More]
Study finds that ambivalence is common among liver donor candidates

Study finds that ambivalence is common among liver donor candidates

Living donors are important to increasing the number of viable grafts for liver transplantation. A new study published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, found that ambivalence is common among donor candidates. [More]
Liver injury caused by herbals and dietary supplements increases 20% in U.S. study group

Liver injury caused by herbals and dietary supplements increases 20% in U.S. study group

New research shows that liver injury caused by herbals and dietary supplements increased from 7% to 20% in a U.S. study group over a ten-year period. [More]
Research findings call for clinical testing of relevant drugs to prevent NASH

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation. [More]
Advertisement
Advertisement